These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 29339316)

  • 21. Treatment of Neuromyelitis Optica Spectrum Disorders.
    Chan KH; Lee CY
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromyelitis optica and neuromyelitis optica spectrum disorders.
    Marignier R; Cobo Calvo A; Vukusic S
    Curr Opin Neurol; 2017 Jun; 30(3):208-215. PubMed ID: 28306572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders.
    Jarius S; Franciotta D; Bergamaschi R; Wildemann B; Wandinger KP
    Clin Chem Lab Med; 2010 May; 48(5):659-63. PubMed ID: 20184532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and classification of neuromyelitis optica (Devic's syndrome).
    Drori T; Chapman J
    Autoimmun Rev; 2014; 13(4-5):531-3. PubMed ID: 24424197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
    Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).
    Trebst C; Jarius S; Berthele A; Paul F; Schippling S; Wildemann B; Borisow N; Kleiter I; Aktas O; Kümpfel T;
    J Neurol; 2014 Jan; 261(1):1-16. PubMed ID: 24272588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saudi consensus recommendations on the management of Neuromyelitis Optica Spectrum Disorders (NMOSD).
    Shosha E; Aljarallah SA; Al Fugham N; Al-Jedai AH; Al Luqmani MM; Al Malik YM; Al Mudaiheem HY; Al Otaibi HS; Al Thekair FY; Al Thubaiti IA; Al Yafeai RH; Ben Slimane NS; Bunyan RF; Cupler EJ; Mubarki SM; Saeedi JA; Al Jumah MA
    Mult Scler Relat Disord; 2022 Oct; 66():104062. PubMed ID: 35908449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuromyelitis optica spectrum disorder (NMOSD): A new concept.
    de Sèze J; Kremer L; Collongues N
    Rev Neurol (Paris); 2016; 172(4-5):256-62. PubMed ID: 27157418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations.
    Sahraian MA; Moghadasi AN; Azimi AR; Asgari N; H Akhoundi F; Abolfazli R; Alaie S; Ashtari F; Ayromlou H; Baghbanian SM; Moghadam NB; Fatehi F; Foroughipour M; Langroodi HG; Majdinasab N; Nickseresht A; Nourian A; Shaygannejad V; Torabi HR
    Mult Scler Relat Disord; 2017 Nov; 18():144-151. PubMed ID: 29141797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
    Sato DK; Nakashima I; Takahashi T; Misu T; Waters P; Kuroda H; Nishiyama S; Suzuki C; Takai Y; Fujihara K; Itoyama Y; Aoki M
    Neurology; 2013 Jun; 80(24):2210-6. PubMed ID: 23677744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuromyelitis Optica Spectrum Disorders.
    Akaishi T; Nakashima I; Sato DK; Takahashi T; Fujihara K
    Neuroimaging Clin N Am; 2017 May; 27(2):251-265. PubMed ID: 28391784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges.
    Liu C; Shi M; Zhu M; Chu F; Jin T; Zhu J
    Autoimmun Rev; 2022 Jan; 21(1):102921. PubMed ID: 34384938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The spectrum of neuromyelitis optica (NMO) in childhood.
    Tillema JM; McKeon A
    J Child Neurol; 2012 Nov; 27(11):1437-47. PubMed ID: 22859697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuromyelitis optica.
    Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
    Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
    Preziosa P; Amato MP; Battistini L; Capobianco M; Centonze D; Cocco E; Conte A; Gasperini C; Gastaldi M; Tortorella C; Filippi M
    J Neurol; 2024 Jul; 271(7):3879-3896. PubMed ID: 38771385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
    Hyun JW; Jeong IH; Joung A; Kim SH; Kim HJ
    Neurology; 2016 May; 86(19):1772-9. PubMed ID: 27164713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evolution of Devic's neuromyelitis optica spectrum disorders].
    Bernard-Valnet R; Marignier R
    Presse Med; 2015 Apr; 44(4 Pt 1):401-10. PubMed ID: 25535163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromyelitis optica spectrum disorders in children and adolescents.
    Tenembaum S; Chitnis T; Nakashima I; Collongues N; McKeon A; Levy M; Rostasy K
    Neurology; 2016 Aug; 87(9 Suppl 2):S59-66. PubMed ID: 27572863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.